ovarian tumors
Research Topic
Language: English
This is a research topic created to provide authors with a place to attach new problem publications.
Research topics above this in the hierarchy
Research problems linked to this topic
- Endometriosis is a debilitating condition and the exact aetiology is still poorly understood.
- Triple negative breast cancer (TNBC) and high grade serous ovarian cancer (HGSOC) are cancer types highly enriched for BRCA germline mutations.
- Deep infiltrating endometriosis (DIE) is a chronic disease with an unknown pathogenesis.
- Ovarian cancers express highly immunogenic tissue-specific antigens.
- Endometrial cancer drug treatments often produce undesirable effects.
- Endometrial carcinoma (EC) is the most common gynecological malignancy in the western world.
- The adverse prognosis of most patients with ovarian cancer is related to recurrent disease caused by resistance to chemotherapeutic and targeted therapeutics.
- Primary endometrial squamous cell carcinoma is a rare variant of uterine epithelial malignancy.
- Despite the nondisputable progress in treatment of ovarian cancer, it still brings serious challenge to the doctors and poor prognosis to the majority of patients.
- Borderline ovarian tumors comprise a unique group of noninvasive ovarian neoplasms with characteristic histology and variable tumor biology that typically manifest as low-stage disease in younger women with resultant excellent prognosis.
- The association of endometriosis with ovarian cancer has been a rare but well-documented phenomenon since 1925, when Sampson first described clear cell carcinoma arising from endometriosis.
- Epithelial ovarian cancer (EOC) is the second most common genital malignancy in women and is the most lethal gynecological malignancy, with an estimated five-year survival rate of 39%.
- High-grade serous ovarian cancer remains the most common sub-type of ovarian cancer and, characterized by high degrees of genomic instability and heterogeneity, is typified by a transition from early response to acquired resistance to platinum-based chemotherapy.